MENU
+Compare
SVRA
Stock ticker: NASDAQ
AS OF
Jan 22, 04:59 PM (EDT)
Price
$2.76
Change
-$0.04 (-1.43%)
Capitalization
475.38M

SVRA Savara Forecast, Technical & Fundamental Analysis

a pharmaceuticals developer

Industry Biotechnology
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SVRA with price predictions
Jan 08, 2025

SVRA's Stochastic Oscillator stays in oversold zone for 5 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SVRA as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SVRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.385) is normal, around the industry mean (15.076). P/E Ratio (0.000) is within average values for comparable stocks, (88.202). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.833). SVRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (264.879).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SVRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SVRA is expected to report earnings to rise 2.64% to -11 cents per share on March 13

Savara SVRA Stock Earnings Reports
Q4'24
Est.
$-0.11
Q3'24
Est.
$-0.11
Q2'24
Missed
by $0.02
Q1'24
Est.
$-0.11
Q4'23
Beat
by $0.01
The last earnings report on November 12 showed earnings per share of -10 cents, meeting the estimate of -10 cents. With 3.26M shares outstanding, the current market capitalization sits at 475.38M.
A.I. Advisor
published General Information

General Information

a pharmaceuticals developer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1717 Langhorne Newtown Road
Phone
+1 512 614-1848
Employees
37
Web
https://www.savarapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UANQX53.520.71
+1.34%
Victory Nasdaq 100 Index Class A
FCGEX20.110.15
+0.75%
NYLI PineStone Global Equity Class A
CLVRX33.52N/A
N/A
Calvert US Large Cap Value Rspnb Idx R6
VLCRX6.53-0.04
-0.61%
Voya Large Cap Value Port R6
TPVIX19.94-0.22
-1.09%
Timothy Plan Small Cap Value I

SVRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with KYMR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-1.07%
KYMR - SVRA
44%
Loosely correlated
+0.98%
LRMR - SVRA
42%
Loosely correlated
+0.87%
ATXS - SVRA
40%
Loosely correlated
-0.92%
SLNO - SVRA
39%
Loosely correlated
-1.50%
PLRX - SVRA
39%
Loosely correlated
-1.36%
More